Languages SpokenEnglish Common ConditionsBased on the training and education, Dr. Molly Campa, MD may treat patients with the following conditions. Please always check with Dr. Molly Campa, MD directly about which exact conditions he treats. - Stretch Marks
- Unwanted Tattoos
- Razor Bumps
- Nail Fungus
- Scars
- Jowls
- Smoker Lines
- Loose Facial Skin
- Excessive Sweating
- Oily Skin
- Hair Loss & Thinning Hair
- Eczema
- Crow's Feet
- Frizzy Hair
- Dandruff
- Aging Skin
- Saggy Breasts
- Rosacea
- Keratosis Pilaris
- Smile Lines
Prescribed MedicationsKetoconazole Triamcinolone Acetonide Clobetasol Propionate Desonide Doxycycline Hyclate Hydroxychloroquine Sulfate Ciclopirox Taltz Autoinjector (Generic Name: ixekizumab) Hydrocortisone Spironolactone Research PublicationsApproximately 46% of Dermatologists in Austin, TX have available research publications A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies. Molly Campa, Alan Menter Expert opinion on investigational drugs 2016-09-30 Blue Nevus-Like Metastasis of a Cutaneous Melanoma Identified by Fluorescence In Situ Hybridization. Molly Campa, Mahir Patel, Pamela Aubert, Gregory Hosler, Daniel Witheiler The American Journal of dermatopathology 2016-09 Erratum to: A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis. Molly Campa, Bobbak Mansouri, Richard B Warren, Alan Menter Dermatology and therapy 2016-06 Developing more open and equitable relationships with industry to improve advancements in clinical research in dermatology. M Campa, C Ryan, A Menter The British journal of dermatology 2016-06 Radiation-induced localized bullous pemphigoid in a patient with breast carcinoma. Molly Campa, Bobbak Mansouri, Barry Wilcox, John R Griffin Dermatology online journal 2016-01-15 A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis. Molly Campa, Bobbak Mansouri, Richard Warren, Alan Menter Dermatology and therapy 2015-12-29 Palmoplantar pustular psoriasis unresponsive to the interleukin-1β antagonist canakinumab. B Mansouri, D Kivelevitch, M Campa, A Menter Clinical and experimental dermatology 2015-09-07 An overview of developing TNF-α targeted therapy for the treatment of psoriasis. Molly Campa, Caitriona Ryan, Alan Menter Expert opinion on investigational drugs 2015-08-08 Payments From Medical Companies(These can include payments from pharmaceutical companies, medical device companies, and other companies.) Dr. Molly Campa, MD has received over $912 in payments from medical companies (98% less than the average Dermatologist in Austin, TX) - Over $800 in payments for Food and Beverage (86% less than the average Dermatologist in Austin, TX)
- Over $112 in payments for Education (37% less than the average Dermatologist in Austin, TX)
ABBVIE INC. - $15.42 payment for Food and Beverage on 06/25/2024 Novartis Pharmaceuticals Corporation - $17.58 payment for Food and Beverage on 10/19/2023 AbbVie Inc. - $28.33 payment for Food and Beverage on 08/31/2023 Arcutis Biotherapeutics, Inc. - $21.15 payment for Food and Beverage on 06/16/2023 AbbVie Inc. - $24.65 payment for Food and Beverage on 03/31/2023 Arcutis Biotherapeutics, Inc. - $21.24 payment for Food and Beverage on 01/20/2023 Janssen Biotech, Inc. - $17.10 payment for Food and Beverage on 10/25/2022 ABBVIE INC. - $22.20 payment for Food and Beverage on 10/19/2022 Janssen Biotech, Inc. - $19.24 payment for Food and Beverage on 10/19/2022 ABBVIE INC. - $29.25 payment for Food and Beverage on 08/26/2022
|